Evolus (EOLS) Share-based Compensation (2017 - 2026)
Evolus' (EOLS) quarterly Share-based Compensation came in at $5.1 million in Q1 2026, down 13.7% YoY from $5.9 million in Q1 2025, and up 132.9% on a QoQ basis from -$15.6 million in Q4 2025.
Evolus (EOLS) Share-based Compensation (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Share-based Compensation data on file, last reported at $5.1 million in Q1 2026.
- Quarterly Share-based Compensation fell 13.7% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$812000.0 (down 195.64% YoY) and the FY2023 annual result came in at $1.5 million, changed N/A from the prior year.
- Share-based Compensation advanced to $5.1 million in Q1 2026, from -$15.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.9 million in Q1 2025 to a low of -$16.1 million in Q4 2024.
- A 5-year average of $412000.0 and a median of $4.3 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 339.82% — and 2023, when it jumped 177.4%.
- Tracing EOLS's Share-based Compensation over 5 years: stood at -$5.9 million in 2022, then sank by 78.26% to -$10.6 million in 2023, then slumped by 51.94% to -$16.1 million in 2024, then grew by 3.31% to -$15.6 million in 2025, then soared by 132.9% to $5.1 million in 2026.
- The last three Share-based Compensation figures came in at $5.1 million (Q1 2026), -$15.6 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.62 Mn |
| Jun 30, 2026 | 5.62 Mn |
| Mar 31, 2026 | 5.12 Mn |
| Mar 31, 2026 | 5.12 Mn |
| Dec 31, 2025 | -15.55 Mn |
| Dec 31, 2025 | -15.55 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | -16.08 Mn |
| Dec 31, 2024 | -16.08 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.78 Mn |
| Jun 30, 2024 | 5.78 Mn |
| Mar 31, 2024 | 5.08 Mn |
| Mar 31, 2024 | 5.08 Mn |